The company is not paying for the NIH study, other
Post# of 72440
This is a great step forward in developing the science, at minimal cost to the company. Even if the company were paying for this, it would be worthwhile. The company also gains credibility by having the NIH want to study Brilacidin.
Anyone actual shareholder who doesn't want the company to continue moving forward with the science might want to ask themself what the mission of a biotech company is.
Why would any actual shareholder want to have all their eggs in one basket?